Alkermes (ALKS) Competitors

Alkermes logo
$46.46 -0.57 (-1.21%)
Closing price 03:59 PM Eastern
Extended Trading
$46.54 +0.07 (+0.16%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALKS vs. ABEO, MEDP, OMCL, AMN, and ROIV

Should you buy Alkermes stock or one of its competitors? Alkermes's main competitors and comparable companies include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Alkermes compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 767.77%. Alkermes has a consensus price target of $55.73, indicating a potential upside of 18.51%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

Abeona Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Alkermes is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abeona Therapeutics$5.82M23.76$71.18M-$1.07N/A
Alkermes$1.48B5.35$241.66M-$0.02N/A

In the previous week, Abeona Therapeutics had 9 more articles in the media than Alkermes. MarketBeat recorded 25 mentions for Abeona Therapeutics and 16 mentions for Alkermes. Alkermes' average media sentiment score of 0.99 beat Abeona Therapeutics' score of 0.44 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has a net margin of -0.02% compared to Abeona Therapeutics' net margin of -160.30%. Alkermes' return on equity of 0.40% beat Abeona Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Abeona Therapeutics-160.30% -44.82% -32.51%
Alkermes -0.02%0.40%0.19%

Summary

Alkermes beats Abeona Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Alkermes compare to Medpace?

Alkermes (NASDAQ:ALKS) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Medpace has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Medpace has higher revenue and earnings than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.48B5.35$241.66M-$0.02N/A
Medpace$2.53B7.23$451.12M$18.0436.25

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Alkermes had 11 more articles in the media than Medpace. MarketBeat recorded 16 mentions for Alkermes and 5 mentions for Medpace. Medpace's average media sentiment score of 1.53 beat Alkermes' score of 0.99 indicating that Medpace is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Medpace has a net margin of 18.24% compared to Alkermes' net margin of -0.02%. Medpace's return on equity of 99.76% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes-0.02% 0.40% 0.19%
Medpace 18.24%99.76%24.47%

Alkermes presently has a consensus price target of $55.73, indicating a potential upside of 18.51%. Medpace has a consensus price target of $649.27, indicating a potential downside of 0.71%. Given Alkermes' stronger consensus rating and higher possible upside, analysts plainly believe Alkermes is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65
Medpace
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.23

Summary

Medpace beats Alkermes on 11 of the 17 factors compared between the two stocks.

How does Alkermes compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

97.7% of Omnicell shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alkermes had 13 more articles in the media than Omnicell. MarketBeat recorded 16 mentions for Alkermes and 3 mentions for Omnicell. Alkermes' average media sentiment score of 0.99 beat Omnicell's score of 0.98 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omnicell
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Omnicell currently has a consensus price target of $57.86, indicating a potential upside of 65.16%. Alkermes has a consensus price target of $55.73, indicating a potential upside of 18.51%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

Omnicell has a net margin of 3.59% compared to Alkermes' net margin of -0.02%. Omnicell's return on equity of 5.69% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Omnicell3.59% 5.69% 3.61%
Alkermes -0.02%0.40%0.19%

Omnicell has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omnicell$1.18B1.36$2.05M$0.9636.49
Alkermes$1.48B5.35$241.66M-$0.02N/A

Summary

Omnicell beats Alkermes on 9 of the 16 factors compared between the two stocks.

How does Alkermes compare to AMN Healthcare Services?

Alkermes (NASDAQ:ALKS) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Alkermes had 8 more articles in the media than AMN Healthcare Services. MarketBeat recorded 16 mentions for Alkermes and 8 mentions for AMN Healthcare Services. Alkermes' average media sentiment score of 0.99 beat AMN Healthcare Services' score of 0.47 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AMN Healthcare Services
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AMN Healthcare Services has a net margin of 3.10% compared to Alkermes' net margin of -0.02%. AMN Healthcare Services' return on equity of 23.42% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes-0.02% 0.40% 0.19%
AMN Healthcare Services 3.10%23.42%7.19%

Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Alkermes currently has a consensus price target of $55.73, indicating a potential upside of 18.51%. AMN Healthcare Services has a consensus price target of $39.17, indicating a potential upside of 2.94%. Given Alkermes' stronger consensus rating and higher probable upside, analysts plainly believe Alkermes is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65
AMN Healthcare Services
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33

Alkermes has higher earnings, but lower revenue than AMN Healthcare Services. Alkermes is trading at a lower price-to-earnings ratio than AMN Healthcare Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.48B5.35$241.66M-$0.02N/A
AMN Healthcare Services$2.73B0.54-$95.70M$2.7513.84

Summary

Alkermes beats AMN Healthcare Services on 9 of the 17 factors compared between the two stocks.

How does Alkermes compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Alkermes has higher revenue and earnings than Roivant Sciences. Alkermes is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$8.26M3,467.54-$299.77M-$0.63N/A
Alkermes$1.48B5.35$241.66M-$0.02N/A

In the previous week, Roivant Sciences had 11 more articles in the media than Alkermes. MarketBeat recorded 27 mentions for Roivant Sciences and 16 mentions for Alkermes. Alkermes' average media sentiment score of 0.99 beat Roivant Sciences' score of 0.50 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Roivant Sciences has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Alkermes has a net margin of -0.02% compared to Roivant Sciences' net margin of -838.21%. Alkermes' return on equity of 0.40% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-838.21% -22.03% -20.55%
Alkermes -0.02%0.40%0.19%

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Roivant Sciences currently has a consensus price target of $46.64, indicating a potential upside of 17.98%. Alkermes has a consensus price target of $55.73, indicating a potential upside of 18.51%. Given Alkermes' higher possible upside, analysts clearly believe Alkermes is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

Summary

Alkermes beats Roivant Sciences on 9 of the 15 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALKS vs. The Competition

MetricAlkermesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.81B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-2,321.8424.2434.3430.11
Price / Sales4.4514.858.005.33
Price / Cash28.0921.8921.0222.34
Price / Book4.224.354.763.85
Net Income$241.66M-$24.19M$3.52B$393.14M
7 Day Performance0.63%-7.26%-5.34%-4.53%
1 Month Performance12.71%-4.96%-3.61%-5.86%
1 Year Performance59.99%-2.87%0.01%-7.78%

Alkermes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
2.602 of 5 stars
$46.46
-1.2%
$55.73
+20.0%
+61.9%$7.81B$1.75BN/A2,050
ABEO
Abeona Therapeutics
3.6244 of 5 stars
$2.54
-39.1%
$21.00
+726.8%
-45.6%$241.32M$5.82MN/A226
MEDP
Medpace
2.6686 of 5 stars
$672.93
+3.0%
$649.27
-3.5%
+10.8%$18.37B$2.53B36.416,200
OMCL
Omnicell
3.1938 of 5 stars
$37.35
+0.0%
$57.86
+54.9%
-0.3%$1.79B$1.18B38.913,450
AMN
AMN Healthcare Services
1.9914 of 5 stars
$38.00
+5.0%
$39.17
+3.1%
+140.4%$1.85B$2.73B13.822,664

Related Companies and Tools


This page (NASDAQ:ALKS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners